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Abstract
HTLV-1 is the etiological agent of adult T-cell leukemia (ATL), the neurological syndrome TSP/
HAM and certain other clinical disorders. The viral Tax protein is considered to play a central role
in the process leading to ATL. Tax modulates the expression of many viral and cellular genes
through the CREB/ATF-, SRF- and NF-κB-associated pathways. In addition, Tax employs the CBP/
p300 and p/CAF co-activators for implementing the full transcriptional activation competence of
each of these pathways. Tax also affects the function of various other regulatory proteins by direct
protein-protein interaction. Through these activities Tax sets the infected T-cells into continuous
uncontrolled replication and destabilizes their genome by interfering with the function of
telomerase and topoisomerase-I and by inhibiting DNA repair. Furthermore, Tax prevents cell
cycle arrest and apoptosis that would otherwise be induced by the unrepaired DNA damage and
enables, thereby, accumulation of mutations that can contribute to the leukemogenic process.
Together, these capacities render Tax highly oncogenic as reflected by its ability to transform
rodent fibroblasts and primary human T-cells and to induce tumors in transgenic mice. In this article
we discuss these effects of Tax and their apparent contribution to the HTLV-1 associated
leukemogenic process. Notably, however, shortly after infection the virus enters into a latent state,
in which viral gene expression is low in most of the HTLV-1 carriers' infected T-cells and so is the
level of Tax protein, although rare infected cells may still display high viral RNA. This low Tax level
is evidently insufficient for exerting its multiple oncogenic effects. Therefore, we propose that the
latent virus must be activated, at least temporarily, in order to elevate Tax to its effective level and
that during this transient activation state the infected cells may acquire some oncogenic mutations
which can enable them to further progress towards ATL even if the activated virus is re-suppressed
after a while. We conclude this review by outlining an hypothetical flow of events from the initial
virus infection up to the ultimate ATL development and comment on the risk factors leading to
ATL development in some people and to TSP/HAM in others.
Introduction
Human T-cell leukemia virus type-I (HTLV-1) is the first
discovered human retroviral pathogen [1]. It has been
firmly implicated with the etiology of an aggressive malig-
nancy known as adult T-cell leukemia (ATL) and of a neu-
rological progressive inflammatory syndrome called
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tropical spastic paraparesis or HTLV-1 associated myelop-
athy (TSP/HAM). In addition, there are indications that it
might be also associated with certain other clinical disor-
ders [2,3]. In culture HTLV-1 can infect a wide variety of
cell types from different species. However, in natural
human infections this virus targets mainly mature CD4+
helper T-cells [4-6], resulting in benign expansion the
infected cells [7]. Clonal or oligoclonal expansion of the
infected CD4+ cells is mostly associated with development
of ATL and 90–96% of the HTLV-I DNA is, indeed, found
to segregate with CD4 cells in the peripheral blood of ATL
patients [4], whereas CD4/CD8 double-positive leukemic
cells are detected in rare cases [8]. CD8+ T-cells might also
be infected [9,10], but their expansion is rather polyclonal
and frequently occurs in asymptomatic carriers. Therefore,
their disease association is unclear yet [11].
Shortly after infection the virus enters into a latent state,
rendering the infected individuals asymptomatic seropos-
itive carriers. About 5% of these individuals develop one
of the viral associated diseases 10 to 40 years after infec-
tion. During latency the viral gene expression in the
peripheral blood lymphocytes (PBLs) of such carriers is
very low. Viral RNA is undetectable by Northern blot anal-
ysis in most of the infected cells (i.e. viral DNA harboring
cells) freshly isolated from their peripheral blood [5],
although it can be detected in some carriers by the highly
sensitive RT/PCR analysis [12]. Furthermore, very little or
no viral proteins are detectable in the carriers' PBLs
[12,13]. Notably, despite this low virus expression,
healthy carriers contain antibodies against viral antigens.
They also display anti HTLV-1 specific cytotoxic T-lym-
phocytes (CTL) activity at variable levels that seem to be
determined by hosts' genetic determinants, particularly by
those associated with their HLA antigens [3,14,15]. Exper-
imental evidence has been reported, pointing to the criti-
cal role of these two anti HTLV-1 immune response arms
in keeping this low viral expression. It has been repeatedly
shown that PBLs isolated from such carries start eliciting
high viral gene expression within few hours of growing in
culture [10,13,16]. However, Tochikura et al. have noted
that addition of sera from HTLV-1 carriers or patients to
the culture medium reduces this viral expression at an effi-
ciency which correlates to their titer of anti HTLV-1 anti-
bodies and that removal of these antibodies by protein A
abolishes this inhibition. No such inhibition has been
observed with sera of uninfected control donors [13].
Other workers have analyzed the level of HTLV-1 expres-
sion in PBLs grown in whole blood samples of various
infected individuals and found that depletion of CTLs
from these samples remarkably increases in the number of
virus-expressing CD4+ cells compared to that found in the
same samples without CTL-depletion [10,16]. Further-
more, these authors have demonstrated a similar increase
by blocking the CTL-mediated cytolytic activity with con-
canamycin A. These data strongly suggest that anti HTLV-
1 CTL activity, mounting in infected individuals, elimi-
nate cells with high level of viral antigens and keep,
thereby, the overall virus expression in the carriers' PBLs at
low level. In view of this low virus expression, the viral
load in HTLV-1 infected individuals has been noted to
expand primarily through proliferation of the proviral
DNA-harboring cells rather than through repeated cycles
of cell-to-cell infection of new uninfected cells [17]. As
discussed in our recent review article [18], this expansion
pattern is widely considered to account for the mainte-
nance of high sequence stability of the viral genome
throughout the hundreds of thousands years of evolution
since its emergence from its simian T-lymphotropic retro-
virus origin. This stability is in striking contrast to the high
genetic diversity of HIV-1 which is known to spread
within the infected individuals through repeated infec-
tions of new cells by cell-free virions [19].
Although the mechanism of HTLV-1 pathogenicity is not
fully understood yet, it is widely believed that a virally
encoded transactivator protein, called Tax, plays a central
role in this mechanism. It should, therefore, be noted that
while the low level of the virus gene expression detected
in latently infected carriers might be sufficient for main-
taining their anti HTLV-1 seropositivity and CTL activity,
the low Tax level, resulting from this reduced viral expres-
sion is, most likely, below its pathogenic threshold. This
implies that generating an HTLV-1 related disease requires
an activation of the dormant virus in order to elevate Tax
to its pathogenic level.
In this article we present a comprehensive review of the
wide range of Tax molecular interactions and biological
effects that might be closely relevant to the mechanism of
ATL genesis and summarize this information by propos-
ing hypothetical flow of a stepwise pathway leading to
this malignancy or to TSP/HAM.
HTLV-1 genomic structure and gene expression
HTLV-1 is a complex retrovirus that, in addition to the two
long terminal repeats (LTRs) and the gag, protease, pol
and env genes, which are typical to most other retrovi-
ruses, its genome contains an additional region called pX,
which resides between the env gene and the 3'-LTR,. This
region includes four partially overlapping reading frames
(ORFs), of which the most investigated ones are ORFs III
and IV that encode for the viral regulatory Rex and Tax
proteins respectively (see illustration in Fig. 1A). The gag,
protease and pol precursor polypeptide is translated from
the full genomic length viral RNA, whereas the env precur-
sor polypeptide is translated from a singly spliced viral
RNA. These precursor polypeptides are cleaved into the
mature functional proteins by the viral protease. Tax and
Rex are translated from a doubly spliced viral RNA, usingRetrovirology 2004, 1:20 http://www.retrovirology.com/content/1/1/20
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Schematic illustration of the HTLV-I genome organization (A) and its various mRNA species with their specific splicing and  encoded protein products (B) (See the text for detailed explanation) Figure 1
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two alternative translational initiation codons as illus-
trated in Fig. 1B.
Tax is present predominantly in the nucleus due to its
nuclear localization signal (NLS) residing at its amino ter-
minus [20,21]. However a substantial portion of Tax is
present also in the cytoplasm due to its newly identified
nuclear export signal (NES) [22]. Tax, which acts as a
dimer [23], was originally discovered as a transactivator of
viral RNA transcription from a promoter located at the 5'-
LTR [24], but later proved to modulate the synthesis or
function of a wide range of cellular regulatory proteins
[25-27]. Rex, on the other hand, acts to promote the
export of the unspliced and singly spliced viral RNAs spe-
cies from the nucleus to the cytoplasm [28] by binding to
a Rex responsive element (RxRE) residing in the 3' R
region of the viral RNA [29]. In addition, there are some
indications that Rex may also inhibit splicing and degra-
dation of the viral RNAs [30]. Thus at high level of Rex
there is a preferential export of the gag-protease-pol- and
of the env-encoding RNA species and low export of the
Tax/Rex-encoding RNA. This leads to a decline in the level
of Rex and Tax proteins and consequently to a reduced
viral RNA transcription. As a result, the Tax/Rex-encoding
RNA is preferentially exported from the nucleus. In this
manner Rex maintains these different RNA species at an
optimal balance required for the virus production. Con-
sistent with this notion Ye et al. [31] have shown that cells
harboring proviral DNA with defective Rex reading frame
produce high level of the doubly spliced tax/rex encoding
mRNA and high level of functional Tax protein, but low
level of p19 Gag protein and undetectable Rex protein. An
alternatively spliced RNA encodes for another protein
from ORF III, termed p21Rex, but its biological function is
unclear [32].
More recently interest has been focused also on ORF I that
encodes for p12 and p27 and ORF II that encodes for p13
and p30 proteins [33]. In contrast to Tax and Rex, which
are encoded by a bicistronic pX mRNA formed by double
splicing of the viral RNA [21,34,35], the other four acces-
sory proteins are encoded by different pX mRNAs formed
by alternative splicing events [33,36]. Pique et al. [37]
have detected CTL activity in HTLV-I infected individuals
against specific peptides from each of these ORF I and
ORF II proteins, indicating that each of them is produced
natural human infections. The functional role of these
accessory proteins is not completely clear yet. Certain
studies have demonstrated that deletions within frame I
and II do not affect the replication and infectivity of
HTLV-1 [36] nor its capacity to immortalize primary T-
cells [36,38]. In contrast, by using molecular HTLV-1
clone, the group of Albrecht and Lairmore has provided
evidence for the critical role of these accessory proteins in
the viral replication and pathogenesis [33]. It has been
shown that ablation of frame I markedly reduced the virus
ability to infect quiescent peripheral blood lymphocyte
(PBLs) [39] and to replicate in a rabbit model [40]. The
explanation suggested by these investigators for the dis-
crepancy between theirs and the others' results regarding
p12 is that the other groups examined the role of this pro-
tein in IL-2/mitogen-activated PBLs, whereas their own
data indicate that p12 is required for HTLV-1 infection in
quiescent PBLs, since when they added a mitogen and IL-
2 to their cultures the p12-defective HTLV-1 clone became
highly infective [33,41]. Notably, p12 localizes to the
endoplasmic reticulum (ER) and is associated with two
ER-resident proteins; calerticulin and calnexin. Calerticu-
lin is a calcium-binding protein that participates in cal-
cium signaling and linked to activation of the
transcription factor nuclear factor of activated T-cells
(NFAT) [42]. In this manner, p12 can activate the HTLV-1
DNA clone-harboring quiescent PBLs and provide the
physiological requirements for its infectivity, or vice versa,
mitogen/IL-2 activation of the PBLs can override the defi-
ciency imposed by the p12-defective clone. Since HTLV-1
targets quiescent T-cells in natural infection, these find-
ings suggest an important role of p12 protein for the virus
in vivo infectivity.
The frame II encoded p30 protein has been shown to
localize to the nucleus and to function as a transcription
factor. Transient transfection experiments have demon-
strated that this protein can modulate the expression of
various promoters and to activate HTLV-I LTR expression
independently of Tax [43]. It was also shown to interact
with the transcriptional co-activators CREB-binding pro-
tein (CBP) and p300 [44]. Together, these and other data
indicate that p30 may account for the activation of several
genes in HTLV-1 infected cells [44] and play an important
role in the virus replication [45] and maintaining high
viral load in in-vivo infection [33,39,46]. In contrast, a
recent study by Nicot et al. [47] have shown that p30
rather inhibits HTLV-I expression by binding to the tax/
rex-encoding doubly spliced viral RNA and retaining it in
the nucleus. In this manner p30 prevents the synthesis of
Tax and Rex proteins and interferes, thereby, with the pro-
duction of viral particles. Furthermore, high level of p30
has been found to interfere with Tax-induced activation of
HTLV-I LTR [44]. In view of these data it has been sug-
gested that by reducing HTLV-I expression high level of
p30 protects the infected cells from the anti HTLV-I
immune response and contribute, in this manner to the
virus persistence [33]. The other frame II-encoded protein,
p13 localizes in the mitochondria and alters its morphol-
ogy and function [48]. This protein has been shown to be
also essential for maintaining high viral load in rabbit
[45,46]. It has been also demonstrated that p13 interferes
with the phosphorylation of the guanine nucleotide
exchanger Vav protein in T-cells [49].Retrovirology 2004, 1:20 http://www.retrovirology.com/content/1/1/20
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Fig. 1 describes schematically the viral genome organiza-
tion, its various mRNA species and the encoded proteins.
Since Tax protein is widely regarded as a key element in
the HTLV-1 related leukemogenic process. We will discuss
in the following sections the molecular activities and bio-
logical effects of Tax that seem to contribute to its onco-
genic potential.
Modulation of viral and cellular gene expression by Tax
Tax-mediated activation of CREB/ATF-dependent gene expression
As noted before, Tax was initially discovered as a transac-
tivator of the HTLV-1 gene expression [24]. It activates the
viral LTR through three imperfectly conserved 21 bp
repeats called Tax responsive elements (TxRE) [50], which
contain a centered sequence TGACG(T/A)(C/G)(T/A) that
is imperfectly homologous to the consensus cAMP
responsive element (CRE; TGACGTCA) [51]. This ele-
ment, which is also referred to as domain B of the TxRE, is
flanked by a short G-rich stretch (AGGC) at its 5' side,
termed domain A and a C-rich stretch (CCCC) at its 3'
side, termed C domain C [27,51] (Fig. 2A). Although sev-
eral basic leucine zipper (bZIP)-containing proteins,
belonging to the CRE-binding/activating transcription
factor (CREB/ATF) family, can bind to this viral CRE [52]
only few of them can efficiently mediate the Tax-induced
transactivation of HTLV-1 LTR [53-56]. A recent investiga-
tion of the effect of negative transdominant constructs
against various bZIP proteins of this family has provided
evidence that CREB is the most prominent factor that
cooperates with Tax in activating HTLV-1 LTR expression
[53]. Numerous earlier studies have demonstrated that in
the absence of Tax, CREB forms unstable complex with
the viral CRE, whereas Tax acts to stabilize this complex.
By interacting with the bZIP region of CREB Tax enhances
CREB dimerization and increases, thereby, its affinity to
CRE [54,57-59]. This Tax-CREB-TxRE complex is further
stabilized by direct binding of Tax to domains A and C of
the TxRE through its N-terminus [60,61] (Fig. 2A). This
stabilized binding enables Tax to recruit to the ternary
Tax-CREB-TxRE complex the co-activators CREB binding
protein (CBP) and its homologous protein p300 by bind-
ing to their KIX domain through its kinase-inducible
domain (KID) [62] and the p300/CBP-associated factor
(P/CAF), which binds through it carboxy terminus to a
distinct site located around amino acid 318 to 320 of the
Tax protein [63]. These three co-activators exert their effect
by histone acethylation, which induces chromatin confor-
mational modification at the site of the target promoter
and facilitates, thereby, the interaction of the enhancer-
bound transcriptional activators with the TATAA box-
associated basal transcriptional factors [27] (Fig. 2A).
Interestingly, however, Jiang et al. have shown that P/CAF
can bind Tax without CBP or p300 and enhances its stim-
ulatory effect on HTLV-1 LTR transcriptional expression
independently of histone acetylation [63]. In contrast,
several other studies have indicated that CREB2 (called
also ATF-4), a member of another bZIP protein family,
plays a more central role in Tax activation of HTLV-1 gene
expression. These studies show that while in the absence
of Tax, CREB can activate HTLV-1 LTR expression only if
phosphorylated by protein kinase A (PKA), CREB2 can
markedly activate the viral LTR without phosphorylation
and that this protein mediates a much stronger activation
of the viral LTR by Tax than CREB does [64-66].
Of particular note are also the recent observations that
when two copies of the TxRE are placed upstream to
TATAA boxes from HTLV-1 LTR or from other promoters,
the strongest activation by Tax is detected with the TATAA
box of the HTLV-1 LTR, indicating that this TATAA box
contains a specific Tax responsive element. Furthermore,
these studies have also revealed that beside of the enhanc-
ing effect Tax on the association of the TATAA-box bind-
ing protein (TBP) to the TATAA site, Tax has an additional
stimulatory effect that is directed towards a step occurring
after the assembly of the basal transcriptional factors onto
the TATAA box [53].
Many cellular genes contain in their promoters a consen-
sus CRE element and are activated by signals that elevate
the cellular cAMP level. The elevated cAMP activates PKA
to phosphorylate CREB which, in turn, binds to CRE and
to CBP/p300. However, there is a substantial controversy
on whether Tax can activate only the viral CRE in its con-
text with the CG-rich flanking domains in the viral LTR
[25,61], or also CRE located in cellular promoters [67,68].
In addition, there are data demonstrating that Tax uses the
CREB/ATF factors to repress the expression of certain
genes, like the cyclin A [69], p53 [70] and c-myc [71]. This
CRE-dependent effect of Tax on such cellular genes may
contribute to the initiation of an oncogenic process by
impairing the cell cycle and growth control.
Tax mediated activation of SRF-dependent gene expression
HTLV-1 infected and Tax-expressing T-cell lines display
increased expression of immediate early genes such as c-
Fos, c-Jun, JunB, JunD and Fra-1, which are components
of the dimeric transcription factors AP1, Egr-1 and Egr-2
[72], fra-1 [73], Krox-20 and Krox-24 [74]. Formation of
these transcription factors is normally activated by the
serum responsive factor (SRF) in response to various
mitogenic signaling agents like serum, lysophosphatidic
acid (LPA), lipopolysaccharide (LPS), 12-O-tetrade-
canoylphorbol-13-acetate (TPA), cytokines and tumor
necrosis factor-α (TNFα). SRF acts through an SRF respon-
sive element (SRE) residing in the promoters of these
genes [75]. The SRE region actually contains two binding
sites; a CArG box [CC(A/T)6GG], and an upstream Ets box
[GGA(A/T)]. After binding to the CArG box, SRF proteinRetrovirology 2004, 1:20 http://www.retrovirology.com/content/1/1/20
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interacts with the ternary complex factors (TCFs), which
consequently bind to the upstream Ets box. In addition,
SRF requires for its transcriptional activity the CBP/p300
and p/CAF co-activators [76].
Tax activates these immediate early genes by interacting
with SRF [77,78] and with TFCs, CBP/p300 and P/CAF
[76] (Fig. 2B). Moreover, AP-1, which is highly expressed
in HTLV-1 infected T-cells [79], regulates the expression of
multiple genes essential for cell proliferation, differentia-
tion and prevention of apoptosis [80], so that by activat-
ing SRF, Tax can also indirectly induce a wide variety of
such cellular genes. Thus, constitutive activation of such
genes in HTLV-1 infected T-cells independently of specific
external signals might be a trigger for initial steps in the
oncogenic transformation of HTLV-1 infected T-cells in
culture as well as in human infection.
Tax-mediated activation of NF-κB-dependent gene expression
A substantial part of Tax oncogenic potential is attributed
to its ability to activate transcription factors of the NF-κB
family, since these factors regulate the expression of
numerous cellular genes [81] associated with diverse bio-
logical processes, such as embryonic development,
immune and inflammatory responses, cell growth, apop-
tosis, stress responses and oncogenesis [25,82-84]. The
NF-κB factors are functionally related to the c-Rel proto-
oncogene and include the p50(NF-κB1), p52(NF-κB2),
p65(RelA), RelB and c-Rel proteins, which act in various
combinations of homo- and heterodimers displaying dis-
tinct specificities. They share a common domain of 300
amino acids, termed Rel homology domain (RHD),
which is involved in their dimerization, DNA binding and
nuclear localization. The p65:p65 and p65:p50 κB are the
most prominent dimers involved in NF-κB-dependent
transcriptional activation, whereas the p50:p50 dimer is
rather inhibitory [85].
In non-activated state NF-κB factors are trapped in the
cytoplasm, tightly associated with inhibitory proteins
called IκBs, primarily with IκBα and IκBβ. These inhibi-
tors contain ankyrin repeats through which they bind to
the RHD of the NF-κB factors and mask their nuclear
localization signal (NLS) [86]. In addition, these com-
plexes contain the catalytic subunit of protein kinase A
(PKAc) which binds in the cytoplasm to both IκBα and
IκBβ and is held there in an inactive state [87] (see illus-
tration in Fig. 3 No. 1). NF-κB factors are activated in
response to a wide variety of inflammatory cytokines and
mitogens, such as TNF-α, IL-1, IL-6, IL-8, GM-CSF, bacte-
rial lipopolysaccharide (LPS) and stress-inducing factors
[81,83,84] (see Fig. 3, No. 2a and 3a). This activation pro-
ceeds in two phases, one taking place in the cytoplasm
and the other in the nucleus.
The cytoplasmic phase includes phosphorylation of IκBα
on serine32 and serine36 and of IκB  on serine19 and
serine23 (Fig. 3, No. 6), which is followed by their ubiq-
uitination and subsequent proteosomal degradation [88]
(Fig. 3, No. 7). The release from IκBs, activates the associ-
ated PKAc, which phosphorylates the free p65(RelA) fac-
tor at its serine276 (Fig. 3, No. 8). As will be discussed
later in more details, this phosphorylation is essential for
the transcriptional activity the p65(RelA)-containing dim-
ers [87]. In addition, degradation of the IκBs releases the
sequestered NF-κB dimers to translocate to the nucleus
[88] (Fig. 3, No. 9). The phosphorylation of IκBs is carried
out by an IκB kinase (IKK) complex comprised of two cat-
alytic subunits, IKK  and IKK  and a regulator subunit,
IKK  which is called also NF-κB essential modulator
(NEMO) [89,90] (Fig. 3, No. 2a and 3a). IKKα and IKK
share a 52% amino acid identity and a similar domain
structure that includes amino-terminal kinase domain, a
dimerization leucine zipper domain, and helix-loop-helix
motifs, which are involved in regulating their kinase activ-
ity [89,90].
The phosphorylating function of the IKK complex is acti-
vated by upstream kinases such as the NF-κB inducing
kinase (NIK) (Fig. 3, No. 2b), the mitogens-activated pro-
tein kinase/ERK kinase kinase-1 (MEKK1) (Fig. 3, No. 3b)
and certain other signal-activated kinases [91]. NIK phos-
phorylates mainly the IKKα subunit (Fig. 3, No.2b),
whereas MEKK1 activates both IKKα and IKKβ [92] (Fig.
3, No. 3b). Activation of IKKα results from its phosphor-
ylation at serine176 and serine180, whereas IKK  is acti-
vated by its phosphorylation at serine177 and serine181
[93,94]. Despite their high homology, IKKβ is much more
active than IKKα in phosphorylating the IκBs [93,95,96].
This predominant activity of IKKβ over IKKα may be par-
tially explained by the observation that in addition to the
phosphorylation of IKKβ by MEKK1, IKKβ is directly
phosphorylated also by IKKα, [97,98] (Fig. 3, No. 2b). A
recent study has suggested an additional function for
IKKα by showing that p65(RelA) needs to be phosphor-
ylated by this kinase at serine536 in order to be transcrip-
tionally active [99]. The third subunit, IKKγ/NEMO is
devoid of kinase activity. Its role is to serve as a universal
scaffold which connects between the two catalytic IKK
subunits and their upstream activating factors into a large
IKK complex [100,101] (Fig. 4, No. 2b and 3b). Iha et al.,
[102] have shown that these various factors assemble to
the IKK complex through different domains of the IKKγ/
NEMO protein, which could be selectively inactivated,
thus attenuating certain NF-κB activating signals without
affecting others.
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Recently, much interest has been attracted to the nuclear
regulation of the NF-κB transcriptional competence. It has
been shown that after reaching the nucleus p65(RelA) can
bind the CBP/p300 and P/CAF coactivators which are
essential for the transcriptional competence of
p65(RelA):p65(RelA) and p65(RelA):p50 dimers [103].
This binding depends on p65(RelA) phosphorylation at
serine276 by PKA and certain other signal activated serine
kinases [85,87,104-108] (see illustration in Fig. 5, No. 1a
and 1b). This phosphorylation is blocked by an NF-κB-
inducible protein termed SINK, which binds to
p65(RelA). This binding does not affect the nuclear local-
ization of p65(RelA), nor its binding to the target DNA
sites. Instead, by inhibiting p65(RelA) phosphorylation
SINK prevents its association with the CBP/p300 and P/
CAF co-activators, thus creating a negative feedback con-
trol of p65(RelA) transcriptional activity [109]. Another
inhibitor protein, called RelA-associated inhibitor (RAI),
has been identified in the nucleus of certain cell types
where it can interact with p65(RelA) and inhibit its
transcriptional activity by blocking its DNA binding. It
has been proposed that this protein provides an alterna-
tive cell-type specific control of NF-κB-dependent gene
expression [110].
In addition to its cytoplasmic inhibitory function IκBα
plays an important regulatory role in the nucleus too.
IκBα has an NLS signal which enables its translocation to
the nucleus where it is protected from the signal-induced
degradation described above [111]. Within the nucleus
IκBα binds to the nuclear p65(RelA) and abrogates its
transcriptional activity by inhibiting its DNA-binding
[112]. IκBα has also a nuclear export signal (NES) which
mediates the export of the p65(RelA):IκBα complex back
to the cytoplasm via its interaction with the nuclear
exporting protein CRM1 [113] (see Fig. 4, No. 2a, 2b, 2c
and 2d). It has been proposed that as long as the signal-
induced cytoplasmic degradation of the NF-κB-associated
Schematic presentation of Tax biological effects which contribute to its oncogenic potential Figure 5
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IκBα is active, induction of corresponding NF-κB-depend-
ent gene expression can keep going on, whereas upon
termination of this signal the export of the
p65(RelA):IκBα complex from the nucleus may serve as
an immediate terminator of this gene expression. How-
ever, the nuclear association of IκBα with p65(RelA) has
been noted to depend on p65(RelA) acetylation status.
The nuclear p65(RelA) can be acetylated by p300 and this
acetylation avoids the binding of p65(RelA) to IκBα, thus
preserving its transcriptional activity [114]. On the other
hand, the nuclear p65(RelA) can bind to specific isoforms
of histone deacetylase (HDAC) which deacetylate it and
inhibit, thereby, its transcriptional activity by facilitating
its association to IκBα [115]. (see Fig. 4. No. 2e). In con-
trast to this nuclear IκBα function, it has been noted that
signals imposing persistent NF-κB activation, do so by
enhancing the level of unphosphorylated IκBβ, which
binds to p65(RelA) in the cytoplasm without masking its
NLS or interfering with its DNA binding [116] (Fig. 4, No
3a, 3b and 3c). It has been proposed that under such con-
ditions IκBβ escorts p65(RelA) to the nucleus, where it
protects it from the inhibitory effect of the nuclear IκB
and maintains, in this manner, a persistent NF-κB tran-
scriptional activation [116].
IKK  has also been found to have an important role in the
nucleus (Fig. 4, No 4a) where it seems to affect the NF-κB
transcriptional activity in several different ways. In one
study the nuclear IKKα has been shown to bind CBP and
p65(RelA) and to recruit, in this manner, the CBP co-acti-
vator to NF-κB-responsive promoters, where it acetylates
histone H3 and facilitates, thereby, the expression of these
promoters [117] (Fig. 4, No. 4b). Another study has
shown that the nuclear p65(RelA)-associated IKKα stimu-
lates the NF-κB-responsive promoters by directly phos-
phorylating histone H3 with its kinase activity [118] (Fig.
4, No 4c), and a third study has demonstrated that the
nuclear IKKα phosphorylates the nuclear p65(RelA) and
facilitates, thereby, its association with CBP/p300 [99]
(Fig. 4, No 4d).
IKKγ/NEMO too has been noted to translocate to the
nucleus where it regulates the NF-κB transcriptional
activity by competing with the nuclear p65(RelA) and
IKKα for CBP/p300 [119] (Fig. 4, No. 5a and 5b
correspondingly).
In contrast to the transient NF-κB activation by external
signals, NF-κB factors are constitutively activated by
HTLV-1 Tax protein in Tax-expressing and HTLV-1-
infected cells. Reported studies suggest that Tax may exert
this activation in three ways: a) The most widely accepted
concept is that Tax associates with the IKK complex
through the adaptor IKKγ/NEMO subunit. Tax also binds
to the upstream kinases, MEKK1 and NIK and enhances
their kinase activity. In this manner Tax connects these
activated kinases to IKKγ/NEMO and recruits their kinase
activity to phosphorylate IKK  and IKKβ [25,102,120-
122] which, in turn, phoshphorylate IκBα and IκBβ (see
Fig. 3, No. 4a, 4b and 6). A recent study have proposed
that IKKγ/NEMO assembles into the large IKK complex as
a homodimer or homotrimer and that its binding to Tax
enhances its oligomerization [123]. b)  Tax can bind
directly to IKK  and IKK  and activates their kinase activ-
ity independently of their phosphorylation by the
upstream signal-induced kinases [124] (Fig. 3, No. 5 and
6), c) Tax can bind directly to the IκBs and induce their
proteosomal degradation independently of their phos-
phorylation by IKK [90,125] (Fig. 3, No. 10a, 10b and
10c). Thus, Tax induces phosphorylation-dependent or
independent degradation of both of the IκBs and enables,
thereby, the nuclear translocation of the released NF-κB
factors independently of exogenous signals (Fig. 3, No. 9).
A number of studies indicate that the nuclear Tax plays an
important role in establishing the transcriptional activity
of the NF-κB factors reaching to the nucleus. Bex et al.
[126] have demonstrated that the nuclear Tax localizes in
transcriptionally active structures containing the NF-κB
factors p50 and p65(RelA), RNA polymerase II, nascent
RNA and splicing factors. Other studies have shown that
Tax physically binds to the NF-κB factors p65(RelA)
[127], c-Rel [127], p50 [128] and p52 [129] and
enhances, thereby, their dimerization [130], which is
essential for their binding to the NF-κB responsive ele-
ment in the target promoters [127,128]. Tax has noted
also to associate with these factors when they are already
bound to their DNA targets and facilitates their transcrip-
tional activity [127,128]. In contrast, our own experi-
ments, to be published elsewhere (manuscript in
preparation), indicate that the binding of Tax to the free
p65(RelA) factor occurs already in the cytoplasm and then
the two proteins translocate to the nucleus together (see
Fig. 3, No. 11a and 11b). In addition, it has been demon-
strated that by its ability to bind the NF-κB factors [127-
129] on one hand and the CBP/p300 [62,131] and P/CAF
[63] co-activators on the other hand, Tax recruits these co-
activators to the NF-κB factors independently of the above
mentioned serine276 phosphorylation on p65(RelA) (see
illustration in Fig. 4, No 6). However, a recent study has
indicated that in order to be transcriptionally active,
p65(RelA) needs to be phosphorylated by IKKα at
serine536 even when activated by Tax [99]. This phospho-
rylation is mediated by Tax [99] through its capacity to
physically bind IKK  and IKKβ and induce their kinase
activity [124].
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Tax biological effects contributing to its oncogenic 
potential
Enhancing T-cell proliferation
There is ample of literature, reviewed in ref.
[2,3,21,132,133], which demonstrate a modulation of
expression of a wide range of cellular genes by Tax. cDNA
profile analyses have detected several hundreds of Tax
modulated cellular genes [82,134]. Some of them are
directly involved in activation of T-cells proliferation,
such as interleukin 2 (IL-2) [135] and the α subunit of its
receptor (IL-2Rα) [136], which together establish an auto-
crine loop [137], IL-15 [138] and its receptor (IL-15R)
[139], granulocyte-macrophage colony stimulating factor
(GM-CSF) [140], tumor necrosis factor-α (TNF-α) [141],
the MAD1 [142] and others [21]. Tax also activates cyclin
D2 [143], cyclin D3 [144] and cdk6 [145], which are
involved in the cell cycle progression, and inactivates
p16INKA4 [146] which acts to restrain excessive cycle pro-
gression. In addition, Tax affects the functions of many
regulatory proteins by physical binding to them. A recent
protein profile analysis has revealed that Tax can form
complexes with 32 different proteins. Many of them
belong to the signal transduction and cytoskeleton path-
ways and transcription/chromatin remodeling [147].
Constitutive deregulation of such regulatory factors in
HTLV-1 infected T-cells can set the cells into uncontrolled
continuous proliferation. Induction of such a continuous
proliferation of mature T-cells is likely one of the first
steps in the initiation of the ATL leukemogenic process
since it renders the cells more accessible to spontaneous
and exogenously induced mutagenesis.
Induction of genetic instability
Enhancing mutagenesis via telomerase inhibition
Telomeres are specialized nucleoprotein structures
located at the ends of each chromosome. In human they
consist of up to 15 kb long double stranded tracts of tan-
dem TTAGG repeats, ending with a 3' single-stranded
overhangs and are associated with a number of functional
proteins [148]. These structures prevent chromosomes
from fusing end-to-end with each other on one hand and
protect them from degradation by exonucleases on the
other hand. They also enable the cells to distinguish
between ends of broken DNA and natural chromosomal
ends and prevent these natural ends from initiating DNA
damage-specific checkpoint or repair cascades [148]. Tel-
omeres are formed by telomerase, which are present in
germ and embryonal cells and in many cancers but not in
normal adult somatic cells [149]. Hence, in the absence of
telomerase activity the telomeres of normal somatic cells
are progressively shortened in each cell division until they
reach a critical length, at which point the cells enter a qui-
escent viable state and are subsequently eliminated by
apoptosis. However, the same shortening process may
abrogate the telomere's protective effects and allow,
thereby, end-to-end chromosomal fusion that forms
dicentric and multimeric chromosomal structures. Such
structures can break during mitosis at variable points,
resulting in aneuploidy and extensive non-reciprocal
chromosomal translocations and rearrangements. This
chromosomal instability can lead to accumulation of var-
ious mutations, including such that inactivate important
checkpoints or induce a telomere-restoring mechanism,
which may result in immortalization and carcinogenesis
of the cells [150]. This implies that telomerase inactiva-
tion may, actually, play an important role in tumor initi-
ation. Consistent with this notion many established
human cancers maintain stabilized telomere length either
due to mutational telomerase reactivation [149], or acti-
vation of other alternative mechanisms [151].
Of note in this context is, that unlike other types of
human leukemia and lymphoma, ATL cells display
numerous unique chromosomal aberrations [152,153]
resembling those resulting from telomere dysfunction,
frequently seen in solid tumors [149]. Moreover, HTLV-1
Tax has been recently found as capable of inactivating tel-
omerase in a variety of cells [154], suggesting that telom-
erase inhibition in infected cells of HTLV-1 carriers might
be one of the mechanisms by which Tax initiates the ATL-
related leukemic process. This possibility is supported by
data demonstrating that infection of primary peripheral
blood T-lymphocytes with HTLV-1 results in an initial
decline of the cell viability which parallels with reduction
in telomerase activity and that this decline is subsequently
followed by an outgrowth of selected immortal survivors
displaying increased telomerase activity [155]. Additional
support comes from the close correlation observed
between telomerase activity in ATL cell and the clinical
stage of the disease. Leukemic cells of acute ATL patients
display the highest telomerase activity, whereas patients
with less severe clinical stage, whose leukemic cells elicit
high telomerase activity, were noted to rapidly progress to
the acute form, suggesting that the increased telomerase
activity is not a side result of the acute ATL conditions, but
rather one of the causes leading to this stage [156].
Interference with DNA repair
As noted above, HTLV-1 infected T-cells show high fre-
quency of chromosomal abnormalities [152,153]. The
first indication that Tax is associated with cellular genetic
aberration came from the observation that Tax represses
the expression of polymerase-β which is involved in DNA
repair [157]. This notion was later substantiated by dem-
onstrating the capacity of Tax to enhance mutation rate
[158] and other types of genetic instability [159] via
impairing the chromosomal segregation fidelity and inter-
fering with several modes of DNA repair such as the, mis-
match repair (MMR), base excision repair (BER) and
nucleotide excision repair (NER) [160-165]. ParticularRetrovirology 2004, 1:20 http://www.retrovirology.com/content/1/1/20
Page 13 of 24
(page number not for citation purposes)
interest has been focused in the last few years on Tax inter-
ference with NER, since this mode of repair is regarded as
a major mechanism of maintaining the genome stability
and its abrogation has been linked to increased cancer
incidence [166]. However, there are several unresolved
questions regarding the role of some factors in these DNA
repair pathways. For example, Tax has been shown to
enhance the expression of PCNA [167], an essential cofac-
tor of DNA polymerase-δ and  , which are involved with
DNA replication and repair [168]. Mutagenesis analysis
have suggested that the ability of Tax to stimulate PCNA
correlates with its ability to inhibit NER [162]. Based on
this observation it has been proposed that the increase of
PCNA molar ratio over polymerase-δ interferes with the
DNA repair activity of this polymerase without affecting
its function in DNA replication [160,162]. However, this
explanation seems to over-simplify the complex role of
PCNA in coordinating polymerase-δ activities between
DNA replication and DNA repair. Of note in this context
is that moderate levels of p53 also stimulates PCNA [169],
but yet NER is rather enhanced in these conditions [161].
Another explanation has been based on p53 ability to ele-
vate the level of p21WAF-1 which binds to PCNA [170]. It
has been proposed that this binding of p21WAF-1 directs
PCNA towards inhibition of DNA replication without
affecting NER [168] and that Tax can prevent this pathway
by its capacity to inhibit p53 transcriptional activities
[70,171,172]. However, we [173] and others [174] have
shown that Tax also elevates p21WAF-1  and therefore,
should accordingly, be anticipated to enhance NER rather
than to inhibit it. Furthermore, other studies have demon-
strated that p21WAF-1 is not needed for NER [175] or may
even inhibit it [176]. Therefore, more intensive studies are
needed to resolve these conflicts. Of note however, p53
has been found to act also at the early damage-recognition
step of NER [177]. It would be interesting to find out
whether Tax directs its inhibitory effect towards this early
step of NER.
In addition, p53 has been proved to be also directly
involved in BER [178], suggesting that Tax interference
with BER [164] might also be exerted through its inhibi-
tory effect on p53 function. At any rate, this genetic desta-
bilization by Tax is certainly an important element of Tax
oncogenic potential.
Inhibition of topoisomerase I
Topoisomerase I (Topo-I) is involved in DNA synthesis
and maintenance of the genome stability by participating
in DNA repair and chromosome condensation. It alters
DNA topology by transiently breaking one strand of the
DNA, passing the other strand through the break and
finally resealing the break [179]. Tax has been found to
bind to topo-I and inhibit its activity [180], whereas Topo-
I activity has been shown to be stimulated by p53 [181].
Thus Tax may interfere with Topo-I activity also through
its effect on p53. This might be another way for Tax to
destabilize the cellular genome, but more intensive inves-
tigation is required to further substantiate this possibility.
Tax-mediated protection of HTLV-1 infected T-cells from stress-
induced cell cycle arrest and apoptosis
All the above effects of Tax which enhance mutations and
other chromosomal aberrations and interfere with DNA
repair should be expected to induce cell cycle arrest or
apoptosis. This, in turn, should prevent further progres-
sion of the leukemogenic process in the infected cells,
unless such cells can, somehow, escape the cell cycle arrest
and apoptosis. There is a substantial controversy over the
influence of Tax on the cell response to stress insults.
While many studies have demonstrated that Tax protects
cells from stress-induced cell cycle arrest or apoptosis
[182-186], others have shown that it enhances the cell
sensitivity to these stress-induced effects [186-190].
Indeed, cDNA microarray analysis of HTLV-1 Tax express-
ing cells exposed to DNA damage stress signal revealed
elevated expression of pro- as well as of anti-apoptosis
genes [191]. However, results from our [182] and other
laboratories reviewed in ref. [186,191], suggest that in
HTLV-1 producing T-cells the anti-apoptotic effects of Tax
override its potential pro-apoptotic effects. Besides, Tax
has been shown to suppress a wide range of factors partic-
ipating in the apoptosis cascade on one hand and to stim-
ulate factors acting as apoptosis inhibitors on the other
hand [144,185,192,193]. A possible explanation for the
above noted controversy is that in most of the studies pre-
senting Tax pro-apoptotic effect, Tax was over-expressed
through highly potent promoters. Excessive levels of Tax
may, reasonably, sensitize the cells to apoptosis. How-
ever, these experimental conditions do not reflect the sit-
uation in HTLV-1 expressing T-cells, in which Tax cannot
exceed the optimal level required for its replication due to
the Rex-mediated fine regulation of the balance between
the viral RNA species encoding for the gag, pol, prot and
env proteins and those which encode for the Tax and Rex
proteins [28,29] described earlier in this review. In addi-
tion, Tax has been shown to enhance the cell cycle pro-
gression and to release cells from stress-induced cell cycle
arrest [26,145,194].
Experimental models for Tax oncogenicity
Numerous studies have been focused on investigating Tax
oncogenic potential in cultured cells and animal models.
Most of them used plasmids expressing w.t. Tax or various
Tax mutants under the control of HTLV-1 LTR or other dif-
ferent promoters. It was only few years ago that an infec-
tious clone of the entire HTLV-1 genome was constructed
and appropriate cell culture techniques were developed to
introduce this clone into human primary PBLs. This clone
was found as capable of propagating in cultured
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mammalian cells and to transform primary human T-lym-
phocytes [195-197]. This clone opened an opportunity to
study the oncogenic potential of Tax and of various Tax
mutants in the context of the entire viral genome. Some of
the studies to be discussed in this section have been per-
formed with such clones.
Transformation of rodent cells
Tax has been shown to induce neoplastic transformation
of the rat fibroblast Rat-1 [198-203] and the mouse fibro-
blast NIH/3T3 [201] cell lines. Tax has been also shown to
cooperate with the ras oncogene in transforming primary
embryo fibroblasts [203]. Transformation was deter-
mined by formation of foci of morphologically trans-
formed cells, colony formation in soft agar and tumor
formation in nude mice. Several mechanisms have been
proposed to mediate the transformation of Rat-1 cells: 1)
Involvement of NF-κB [199], 2) involvement of CREB/
ATF [68], 3) involvement of phosphoinositide-3 kinase-
PKB/Akt [202] and 4) Stimulation of p21WAF-1 which pre-
vents apoptosis and enhances the replication of the trans-
formed cells [204]. The cooperation of Tax with ras in
transforming primary embryo fibroblasts is postulated to
be mediated by SRF through the CArG elements of SRF
responding genes [198]. It should be emphasized, how-
ever, that maintenance of this transformation phenotype
requires the continuous presence of active Tax and that no
genetic mutation can be identified in these transformed
cells [200]. Therefore, the process leading to this transfor-
mation is unlikely to reflect the entire pathway leading to
ATL because the leukemic ATL barely express Tax [3] and
they are characterized by intensive chromosomal aberra-
tion [152,153,165]. For the most, this transformation
may reflect only the very early steps of the initiation of the
ATL process.
Immortalization and transformation of primary human T-
lymphocytes
A closer insight into the ATL leukemogenesis has been
gained through studies using primary human T-lym-
phocytes. Such experiments have revealed that after infec-
tion in culture with HTLV-1 or permanent transfection
with Tax, primary human T-cells undergo two stages of
cellular changes. In the first stage the cell become immor-
talized but still remain dependent on IL-2 for their growth
[205]. This immortalization has been shown to result
from Tax-induced stimulation of the G1 phase-specific
cyclin-dependent kinases CDK4 and CDK6, increased
expression of signal transduction genes like cyclin G1, c-
fgr, hPGT [206] and p21WAF-1 [204] and to be associated
with mutations conferring increased telomerase activity
[155]. Studies with different Tax mutants, deficient of
CREB/ATF- or NF-κB-activation, have yielded conflicting
results as to which of these two major regulatory pathways
is involved in this Tax-mediated immortalization. While
certain studies have shown that this immortalization
depends on Tax ability to activate NF-κB [207,208], others
have demonstrated that Tax mutants deficient of NF-κB
activation still retain their capacity to induce this immor-
talization [209]. On the other hand, experiments with an
infectious molecular clone of the entire HTLV-1 genome
have shown that disruption of Tax ability to activate CREB
results in preferential immortalization of CD8+ lym-
phocytes, rather than preferential immortalization of
CD4+ lymphocytes seen with the wild-type infectious
clone [210]. In addition, it has been found that disruption
of Tax capacity to interact with CBP/p300 does not affect
its immortalizing potential [195,210].
In the second stage few IL-2-independent clones of trans-
formed cell emerge. Such transformed cells display an IL-
2-independent constitutive activation of the IL-2 receptor
(IL-2R) signaling pathway that includes the Janus kinases
JAK1 and JAK3, and the signal transducers and activators
of transcription STAT3 and STAT5, which are constitu-
tively active in such cells [206,211-213]. Other studies
have shown in such transformed cells a constitutive high
expression of the growth factor independence-1 (Gfi-1)
which is also involved in coffering their IL-2-independent
growth [214]. In addition, intensive studies have been
recently focused on factors participating in a negative reg-
ulation of the IL-2R associated pathway in HTLV-1 trans-
formed T-cells. One of these factors is the SH2-containing
tyrosine phosphatase SHP1. A gradual loss of this
phosphatase has been noted to correlate with the progres-
sion of HTLV-1 infected primary T-cells from the immor-
talization (IL-2 dependence) to the transformation (loss
of IL-2 dependence) stage [213,215]. Changes in other
negative regulators of Jak/STAT/IL-2R pathway have been
noted to vary between different transformed clones and,
therefore, their role in acquiring the IL-2-indepence is
unclear yet [213]. Also notable is that in contrast to the
rodent cells, the HTLV-1 transformed primary human T-
cells display high mutation rate [158] and other genetic
aberrations [159,165,216]. Of particular interest in this
context is the observation that exposure of HTLV-1
infected primary T-cells to carcinogens enhances a step-
wise progression from their IL-2-dependent immortalized
state to the autonomous transformed state [217]. Also
interesting is the association noted between chromosome
changes in such cells and their growth potential [216].
Many of the above changes observed in the HTLV-1/Tax
immortalized and transformed primary human T-cells are
quite analogous to those found in ATL cells. However,
while fresh leukemic cells from ATL patients, as well as
cell lines derived from these leukemic cells, are success-
fully engrafted in SCID mice and their leukemic infiltra-
tion to various organs is similar to that seen in ATL
patients [218], primary human T-cells immortalized orRetrovirology 2004, 1:20 http://www.retrovirology.com/content/1/1/20
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transformed in culture by HTLV-1 infection, Tax transfec-
tion or intruding a molecular clone of the entire HTLV-1
genome, do not show such tumorigenicity in these mice
[196,219]. This observation can be explained by
postulating that during their progression through multi-
ple selection steps in the infected patient the ATL leuke-
mic cells accumulate selected genetic changes conferring
their tumorigenic phenotype, whereas under culture con-
ditions there is no selective pressure for preferential accu-
mulation of such particular mutations.
Tumor induction in transgenic mice
Tax transgenic mice have been widely used as models for
investigating the oncogenic effects of Tax in-vivo, hoping
to get closer insight to the ATL leukemogenic process in
human [220]. A wide range of different tumors have been
described in such animals and it appears that the pro-
moter used to express Tax determines at least partially the
type of the developing tumors. Transgenic mice expressing
Tax through HTLV-1 LTR were found to develop neurofi-
brosarcomas [221], mesenchymal tumors [222] or skele-
tal bone abnormalities [223], but not leukemias or
lymphomas. Mice expressing Tax through the promoter of
CD3ε were found to develop mesenchymal tumors at
wound sites and salivary and mammary adenoma [224].
Only mice expressing Tax through the granzyme B pro-
moter showed Tax expression in mature T-lymphocytes
and developed large granular lymphocytic leukemia
[225]. These studies suggest that Tax alone is capable of
inducing tumors in various tissues, including lymphoid
cells. A possible explanation for the failure of HTLV-1
LTR-Tax to induce leukemia in such animals may be pro-
vided by the observation that expression of this construct
can be detected in various non-lymphoid organs like the
brain, saliva glands, spleen, thymus, skin, muscle, bones
and mammary glands [223,226] but not in the bone mar-
row [223]. It has been proposed that activation of HTLV-
1 LTR expression in lymphoid cells requires the coopera-
tion of the accessory proteins encoded by ORF1 and/or
ORF II of the pX region with Tax protein. Therefore, Tax
alone cannot activate the expression of the HTLV-1 LTR-
Tax construct in these cells, whereas this cooperation is
not needed in other organs. [3,33,226]
Various modes of tumor induction by the transgenic Tax
have been noted so far. Hall et al. [224] have shown that
the mesenchymal and the mammary adenomal tumor
induced by the CD3ε-Tax transgene displayed high levels
of apoptosis which is associated with high levels of Myc,
Jun and p53. In contrast Portis et al. [227] have
demonstrated a Tax mediated functional inactivation of
p53 in the early stage of the large granular lymphocytic
tumor formation by the granzyme B-Tax transgene and
p53-inactivating mutations in a later stage of the tumor
progression. Other studies have demonstrated the impor-
tance of Tax-mediated activation of NF-κB in the induc-
tion of both the lymphoid [228] and non-lymphoid [229]
tumors.
As noted before, continuous Tax expression is required for
maintaining the neoplastic phenotype of Rat-1 cells trans-
formed by Tax in culture [200]. In contrast, suppression of
Tax expression in transformed fibroblasts derived from
tumors of Tax transgenic mice did not affect their growth
rate and ability to form tumors in animals [230], indicat-
ing that Tax was involved only in the initiation of the in-
vivo tumorigenic process, after which the cells continued
to progress through several genetic changes rendering
their neoplastic phenotype independent of Tax.
Conclusive comments about the pathways leading to ATL and TSP/
HAM
In view of the above described pleiotropic effects of Tax,
which are summarized in Fig. 5, it is widely accepted that
the viral Tax protein is a key element in ATL genesis [2].
This implies that generating this malignancy requires
active viral gene expression in the infected T-cells of
HTLV-1 carriers in order to keep Tax protein at an effective
level. However, as noted before, shortly after establishing
the host immune response against the viral antigens,
HTLV-1 virus expression is kept very low and is the level
of Tax. This low Tax level accounts, likely, the "carrier"
state of the infected individuals by supporting a limited
but continuous expansion of the infected CD4+ cells [17]
and for their anti HTLV-1 seropositive states. However,
this low Tax level, plausibly, is insufficient for exerting all
the above described oncogenic effects leading to ATL.
Therefore, over 95% of the infected individuals do not
develop this malignancy, or other HTLV-1 related clinical
disorders, during their entire life [2,3]. Thus, generating
this malignancy would, plausibly, require activation of
the dormant virus in order to elevate Tax to its oncogenic
threshold. Our previous studies [182,231-233] indicate
that this activation can be induced by a variety of stress
agents which are widely present in the daily human sur-
rounding. However, such agents normally induce also cell
cycle arrest or apoptosis, which could be expected to pre-
vent the subsequent progression towards ATL. This para-
doxical conflict was resolved by our observation that Tax
protects HTLV-1 producing human T-cells from stress-
induced apoptosis [182], implying that the Tax protein,
emerging after activation of the latent virus, can rescue the
host cells from the stressed-induced apoptosis. After this
activation step there may, actually, be a progression to
either ATL or TSP/HAM. Intensive studies, reviewed in ref.
[3,234], indicate that genetic factors of the host, mainly
those associated with the HLA histocompatibily complex
class I, are the major factors determining whether the pro-
gression will proceed towards ATL or TSP/HAM [235]. Of
note is that TSP/HAM is characterized by high virusRetrovirology 2004, 1:20 http://www.retrovirology.com/content/1/1/20
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Schematic hypothetical flow of the events occurring between the initial infection with HTLV-I and ATL or TSP/HAM develop- ment (See the text for detailed explanation) Figure 6
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expression [236-238]. Such high virus expression is
widely considered to be a predisposing factor for TSP/
HAM development [239]. We [240] and others [235] dis-
cussed in details in earlier review articles, how this high
virus expression accounts for most of the pathological and
immunological manifestations of this syndrome and cor-
relates with its severity [238]. On the other hand, no or
very little Tax can be detected in the leukemic cells of ATL
patients [3,12,13,16,234]. It has been proved that anti Tax
CTLs mounted in these patients eliminate the rare cells
with high Tax expression and keep, thereby, Tax at very
low level [10,16]. This difference seems to be determined
by the HLA type of the host [14]. It can be postulated that
the immune response of people with HLA types of high
risk for TSP/HAM, permits permanent high expression of
the activated virus, whereas the immune response of peo-
ple with other HLA types probably act to re-suppress the
activated virus. Therefore, progression towards ATL can,
presumably, proceed only if a mutation, that abrogates
one of the important cellular checkpoints, occurs before
the activated virus is re-suppressed. This speculation is
supported by reports showing that the leukemic cells of
most ATL patients carry one or more mutations which
deregulate the formation or function of cellular factors
associated with T-cell replication, cell cycle arrest or apop-
tosis, such as the IL-2 receptor [241], the JAK/STAT pro-
teins [242], the growth factor independence 1 (Gfi) [214],
p53 [243-245], p15INK4B  and p16INK4A  [246], p27KIP1
[247], p16 (CDKN2) [248], pRb [249], surviving [193],
Fas (Apo1/CD95) [250] and caspases [251]. Interestingly,
the leukemic cells of most ATL patient are defective in the
mitotic spindle checkpoint [252], which likely accounts
for the frequent clastogenic and aneugenic chromosomal
abnormalities detected in these cells [153]. However, no
mutation in mitotic checkpoint genes has been identified
in such cells [252]. Instead, the viral Tax protein has been
shown, in one study, to inactivate the function of the
mitotic spindle checkpoint protein MAD1 [142]. In
another study the MAD1 and MAD2 checkpoint proteins,
which normally reside in the nucleus, have been found in
HTLV-1 infected cells to localize predominantly in the
cytoplasm [252]. Since Tax is hardly detected in circulat-
ing ATL cells, it is rather unlikely to ascribe this checkpoint
loss in the ATL cells to Tax activity. It seems more reason-
able to speculate that this loss results from mutations in
other genes which might indirectly affect the proper sub-
cellular localization of these proteins. It is also reasonable
to assume that this and the other mutations in the above
mentioned regulatory genes are, most likely, acquired in
the pre-leukemic stage during a certain time-gap when the
cells are highly susceptible to mutagenesis. We like to pro-
pose that this time-gap is the time when Tax is still highly
active in a large number of circular T-cells due to the puta-
tive activation of the latent virus. It is plausible to assume
that the level of the anti Tax antibodies existing in latent
HTLV-1 carriers is sufficient to repress Tax expression in
the few high virus-expressing CD4+ cells [13] existing
before activation of the latent virus and that existing level
of anti Tax CTLs in such carriers is sufficient to eliminate
these cells [10,16], but neither of these Immune response
arms is sufficient to handle the overwhelming number of
such high virus-expressing cells resulting from the virus
activation. However, this situation is likely temporary and
may plausibly last until the anti Tax antibodies and CTLs
boosted to mount to a sufficiently higher level that can
overcome this large number of high virus-expressing cells.
This is the time-gap during which we thing that the pre-
leukemic cells are most susceptible to mutagenesis and
can acquire one or more of the above mentioned check-
point-abrogating mutations. If, after the occurrence of
such mutations, Tax expression is re-suppressed by the
mounting level of the anti Tax antibodies and cells that
still remain with high virus expression are eliminated by
the mounting CTLs, this will not stop the remaining
mutant cells to further accumulate additional mutations
and progress towards ATL. This re-suppressed Tax expres-
sion will avoid exposure of the progressing cells to anti
Tax CTLs. However, since the probability for such particu-
lar mutations to occur during this limited time-gap might
be very low, it is quite possible that multiple episodes of
such virus activation and re-suppression may occur in
HTLV-1 carriers before progression to ATL can be turned
on. Such flow of events, which is illustrated in Fig. 6, may
explain why ATL usually develops after much longer clin-
ical latency than TSP/HAM.
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